Gene Therapy is the transfer of genetic material (gene transfer) to dysfunctional cells to correct a deficiency in the DNA or genome of a patient. Cell Therapy, such as stem cell therapy, can also be used to achieve these goals. Gene therapy can be applied to genetic disorders as well as diseases acquired over the lifetime of an individual, such as cancer or infection, to confer a specific property to the cell allowing it to combat the disease.

For more information browse our education section.

Benefits include:

1. Establishment and maintenance of a page devoted to your company, its products and services in the relevant section of our website (linked to from our homepage for a fixed period of time; at least 3 months)

2. Unlimited advertising on the site in sections chosen by you, e.g. banner or box ads

3. Unlimited posting of job vacancies in your company

4. Full page advert in the yearly print issue distributed by EBSCO and available for purchase through Amazon

5. Unlimited press releases published on the site, again linked to from the homepage for a fixed period of time (at least 3 months)

6. Unlimited articles describing the application of your technology

7. Yearly support to enable updates to your company page

8. Advanced ad tracking system to monitor who is clicking your ads and viewing your page

For a limited time period we are now charging an introductory price of $299 for annual subscription to this service; with revenue obtained from this nominal corporate membership fee helping keep the Gene Therapy Review an open resource for the broader scientific community.

If you are interested in listing your company on the Gene Therapy Review please contact the Editor-in-Chief, Dr Michael Roberts at mlroberts@genetherapyreview.com

Currently the board consists of:

Editor-in-Chief: Michael L Roberts, PhD

Dr Roberts has more than 15 year experience in the Gene Therapy Sector, graduating from Glasgow University with first class honours and receiving his PhD from Cambridge University (Magdalene). He has post-doctoral research experience at Royal Holloway and the National Hellenic Research Foundation as a Marie Curie Fellow. After serving on the board of Regulon and directing R&D, he founded Synpromics, where he is President and CEO.

Associate Editor: Maria Vougiouka, BSc

Ms Vougiouka has more than 10 years experience in the scientific publishing sector. She played a key role in setting up Gene Therapy Press, where she administered two peer-reviewed journal; Gene Therapy and Molecular Biology (GTMB) and Cancer Therapy. She also has accrued several years experience in the regulatory industry where she worked for Wyeth and Pfizer.

Editorial Board Members

Jani K Raty, PhD – Head of Information Management, Amsterdam Molecular Therapeutics, The Netherlands.

Pankaj Kumar, PhD – Post-Doctoral Research Associate, Binghampton University, NY, USA.

Ekaterina Semenova, PhD – Post-Doctoral Research Associate, UCL Institute of Child Health, London, UK.

The site was founded in 2008 with a view to establishing the most comprehensive gene therapy resource on the web, with content provided by the gene therapy community. If you chose to contribute articles or blog entries to the Gene Therapy Review we will upgrate your account to AUTHOR status after registration, entitling you to edit your own content. Articles will also be published in our print edition, which is published four times a year and is edited by Dr Michael L. Roberts who has more than 15 years experience developing various gene transfer vector systems

If you contribute more than ten articles or blog entries then you may apply for EDITOR status, allowing you to help maintain a section of the Gene Therapy Review. Successful applications depend on the quality of the articles submitted and your experience in the section of interest. For more information on sections please contact us.

Finally, we would like to encourage all users to promote the Gene Therapy Review and their contributions by adding the following line to their email signatures:

Member of the Gene Therapy Review: A free genetics educational resource – http://www.genetherapyreview.com

As users progress through the levels of membership they may update this signature to reflect their status. We hope that this will help raise awareness of the Gene Therapy Review and hence promote your own contributions and the profile of our resource as a whole.

Please also ensure that your profile details are up-to-date. You can access and edit your profile page after you register and log in using the links in the User Menu on the left-hand side of each page.

Gene Therapy News: All the breaking news in the gene therapy arena can be found in our news pages. You can read how the latest research will likely impact on the field in analysis. For those seeking employment in the sector, we have established a job bulletin board, where academics are invited to advertise for free.

Gene Therapy Research: We provide links to the home pages of all the academic research groups devoted to human genetics, gene therapy and stem cell research. In the companies section we detail the status of private sector DNA research. You can also follow their progress in our literature section where all the latest genetic engineering articles are listed

Gene Therapy Companies: We review the companies that are developing new gene transfer technologies and list the service providers that offer contract manufacturing or contract research to the field. Information on genetic disorders, cancer and infectious disease (current targets of gene therapy research) is also provided, with links to further reading on each topic.

Gene Transfer Vectors: Our gene vector pages to learn more about gene transfer into human cells. We describe all the current techniques used for gene delivery. Our technical pages also serve as a source for all commerical gene transfer vectors. These pages have links to plasmid maps, DNA sequences and manuals.

Gene Therapy Clinical Trials: Our clinical trial section contains a database containing all the published results from current and past clinical trials. For those considering enrolling in a clinical trial, a list of patient resources is also provided where we focus on genetic disorders, cancer and infectious disease. The regulatory pages provide links to the interational bodies that control clinical trial research.

Gene Therapy Literature: Our literature section contains analysis of the latest articles published in the leading gene therapy journals. You can also search pubmed from this section. Activities of the various gene therapy societies are listed and we provide a calender of all the annual international scientific congresses focussing on human genetics.

We hope you find our site useful and encourage you to leave comments as to how we can improve.

Warmest Regards,

The Editorial Team

Address: Native Remedies, LLC
6531 Park of Commerce Blvd., Suite C-160
Boca Raton, Florida 33487
U.S.A

Researchers say previous attempts to correct the gene mutation that predisposes young people to emphysema have failed to achieve lasting results.

But a new study shows a different approach that targets cells known as alveolar macrophages to deliver the gene therapy to the lungs of mice with this form of inherited emphysema was successful in treating the condition for two years.

Emphysema is a progressive lung disease that causes severe shortness of breath. There is no cure for the disease.

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced a broad collaboration with Ortho-McNeil, Inc., a Johnson & Johnson
company, to discover, develop and commercialize antisense drugs to treat metabolic diseases, including Type 2 diabetes. As
part of the collaboration, Isis will grant to Ortho-McNeil worldwide development and commercialization rights to two of its
diabetes development candidates, ISIS 325568 and ISIS 377131, which selectively inhibit the production of glucagon receptor
(GCGR) and glucocorticoid receptor (GCCR), respectively. Additionally, Ortho-McNeil will provide funding to Isis to support the joint discovery of novel drugs to treat metabolic diseases, including diabetes and obesity. After the initial collaboration phase,
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) will continue development of these drugs.
Ortho-McNeil will pay Isis a $45 million upfront licensing fee, and will provide Isis with research and development funding over
the period of the collaboration. In addition to the licensing fee, Isis could receive over $230 million in milestone payments upon
successful development and regulatory approvals of ISIS 325568 and ISIS 377131, as well as royalties on sales. Isis could also
receive milestones and royalties on the successful development and regulatory approvals of additional drugs discovered as
part of the collaboration. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Prior
to closing of the transaction, Isis plans to purchase the equity in Symphony GenIsis, Inc. and reacquire the intellectual property
related to the GCGR and GCCR programs as well as regain full ownership of ISIS 301012, the Company’s lipid-lowering drug
targeting Apolipoprotein B-100.
“We look forward to working with Ortho-McNeil, Inc. and J&JPRD to advance our glucagon receptor and glucocorticoid receptor
drugs through the clinic and to develop additional drugs against other promising targets,” said Lynne Parshall, J.D., Executive
Vice President and Chief Financial Officer, Isis pharmaceuticals. “This collaboration represents another major step for us in capturing value from our achievements in creating a new drug discovery platform technology and discovering commercially attractive antisense drugs.”
“This collaboration has been enabled by the productivity of our metabolic drug discovery program, which has evaluated more
than 120 targets in animal models using antisense drugs,” said Jeffrey Jonas, M.D., Executive Vice President, Isis
Pharmaceuticals. “Both ISIS 325568 and ISIS 377131 have broad and exciting therapeutic profiles that include lowering of
blood lipids and body fat, in addition to significant glucose-lowering effects. These drugs have demonstrated robust effects in extremely diabetic and hyperlipidemic animals and have demonstrated a unique and preferential distribution to tissues such as liver and fat, thereby potentially minimizing the systemic side effects that would be expected with traditional approaches against the same gene targets. We are enthusiastic about our research collaboration, which should allow us to discover additional
drugs against novel targets, thereby adding to our strong pipeline in this therapeutic area.”
About glucagon receptor (GCGR), target of ISIS 325568
Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In Type 2 diabetes,
unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using
antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and
help control Type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to improved glucose control and reduced
levels of blood triglycerides without producing hypoglycemia.In addition, treatment with ISIS 325568 led to an increase in
circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing
insulin secretion.

About glucocorticoid receptor (GCCR), target of ISIS 377131
Glucocorticoid hormones have a variety of effects throughout the body, including promoting liver glucose production and fat
storage. Although inhibition of GCCR has long been recognized as an attractive strategy for development of therapeutics for
Type 2 diabetes, the side effects associated with systemic GCCR inhibition have challenged development of traditional drugs.
Antisense inhibitors of GCCR take advantage of the unique tissue distribution of oligonucleotides that allows the antisense
drugs to antagonize glucocortocoid action primarily in liver and fat tissue. Notably, antisense drugs do not reduce GCCR
expression in the central nervous system or adrenal glands — inhibition of GCCR expression in these two organs can lead to
systemic side effects. In preclinical studies, Isis has shown that ISIS 377131 has a broad therapeutic profile that includes
reduction of blood glucose levels, a dramatic and favorable effect on lipid levels including cholesterol and triglycerides, and a
reduction in body fat.

In this trial, which began in March 2006, researchers injected a dystrophin gene compound called Biostrophin, which was developed with MDA support at Asklepios Biopharmaceutical in Chapel Hill, N.C., into the biceps muscles of boys with DMD.
Biostrophin is a combination of miniaturized dystrophin genes and adeno-associated viral shells that home to muscle fibers.

“The patients have been injected with the gene carried by an adeno-associated virus into one muscle of the arm,” said neurologist Jerry Mendell, director of the Gene Therapy Center and the clinician on the study. He also serves as co-director of the MDA clinics at Nationwide Children’s and Ohio State University Hospitals in Columbus. Mendell injected the children at Nationwide Children’s Hospital.

“The patients have been carefully followed for side effects of the treatment, and none have been encountered,” he said. “This is primarily a safety trial, and we can confidently report that safety has been achieved. An additional goal is to lay the ground work for future gene therapy trials by establishing the ideal dose for treatment. In this trial, two doses have been tested, and another will be required before completion of the study.” Mendell said the three additional trial participants will “receive a higher dose, which by all indications will be safe to administer.” {No participants are being recruited at this time.}

“Upon completion of the trial in nine subjects, we will be able to report to the scientific community and the public the results of the trial,” he said, “with recommendations for future gene therapy trials for this devastating form of muscular dystrophy.”

Lisa Baumbach-Reardon, an associate research professor and head of the Neurogenetics Laboratory at the University of Miami (Fla.), who received MDA support for this work, led the study team with Alfons Meindl at Technical University Munich (Germany). The researchers published their findings in today’s issue of the American Journal of Human Genetics.

Having a second gene identified that causes symptoms of SMA is extremely important, not only for the development of better diagnostic tests but also for the development of new animal models and new therapeutic approaches,” said Sharon Hesterlee, MDA vice president for translational research.

The vast majority of SMA cases are caused by a mutation in the SMN1 gene on chromosome 5, which was identified in the mid-1990s. The chromosome-5 form of the disease affects both sexes and ranges in severity from the very severe and often-fatal infantile-onset form (type 1) to the somewhat less severe forms, type 2 and type 3.

The X-chromosome form of the disease, which affects male babies, occurs in a small percentage of SMA cases. Its exact incidence is unknown.

The disease closely resembles the type 1, chromosome-5 form of SMA in all respects except that it also affects the joints, which are not affected in chromosome-5 SMA.

The X-linked disease, which is present at birth, results in low muscle tone, absent reflexes, and multiple contractures (frozen joints) in association with loss of muscle-controlling nerve cells (motor neurons) in the spinal cord. It leads to death within two years.

The underlying genetic cause is any of a number of abnormalities (mutations) in a gene on the X chromosome that carries instructions for “ubiquitin-activating enzyme E1” (UBE1). This enzyme’s normal job in cells is to help attach ubiquitin molecules to proteins the cell needs to destroy. The ubiquitin “tag” marks proteins for destruction. Altered function of this protein disposal system is the likely mechanism by which X-linked SMA occurs.

The investigators screened four North American, one Mexican and one Thai family in which X-linked SMA was suspected and compared their X chromosomes to X chromosomes from unaffected people.

They screened 3,550 chromosomes from unaffected people for two of the UBE1 mutations suspected of causing X-linked SMA and found no instances of either mutation. A third suspected mutation in the same gene was not found in 7,914 chromosomes from people without the disease.

“This study is the culmination of 15 years of investigation, starting with identification of the first families with X-linked SMA, through years of gene-mapping studies to finally, last year, gene discovery and mutation identification.

“It’s been a long road, but we never gave up, because we promised the families who have this devastating illness that, with their participation in our research studies, we would someday identify the causal disease gene,” Baumbach-Reardon said. “Along the way, we’ve worked with an international team of geneticists, genetic counselors and scientists. We all share in the excitement and the hope that this discovery brings.”

About MDA

MDA is a voluntary health agency working to defeat more than 40 neuromuscular diseases, including SMA, through programs of worldwide research, comprehensive services, and far-reaching professional and public health education. For more information, visit www.mda.org.

The results could pave the way for human trials early next year, say researchers who developed the system at the Cedars-Sinai Medical Center in Los Angeles.

Previous attempts to treat glioblastomas with gene therapy failed because some tumour cells survived and regrew. The new treatment overcomes this problem by permanently priming the immune system to pick off any straggler tumour cells.

A harmless virus that only infects fast-dividing cancer cells is injected directly into the brain, and used to deliver the therapeutic genes into the tumour. One gene, HSV1-TK, kills the cancer cells by activating ganciclovir, an otherwise ineffective drug administered into the rat’s abdomen. Yet the key to the therapy’s long-term success is a second gene, Flt3L, which summons immune “dendritic” cells from the bloodstream into the brain.

These cells engulf the debris and transport it back to lymph nodes, where they re-prime the immune system to attack any remaining tumour cells during and after treatment. The work will appear in Molecular Therapy
For more details

http://www.newscientist.com/article/mg19726444.900-fatal-brain-cancer-tamed-by-gene-therapy.html

Score another one in the loss column for gene therapy. Cambridge, MA-based Genzyme said yesterday at a medical meeting that its gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility.

The trial—one of the largest in the field of gene therapy—enrolled 289 patients who were injected with either a placebo or a low, medium, or high dose of Genzyme’s gene therapy treatment, researchers said at the American College of Cardiology meeting in Orlando, FL. The treatment, designed to deliver a copy of a gene called HIF1a, was supposed to help stimulate the growth of new blood vessels around clogged arteries in the legs, improving circulation and allowing people with severely limited mobility to walk for longer periods of time.

The Gene Therapy Review announces its new partnership with EBSCOhost, an agreement that will see its content distributed worldwide in a multitude of libraries. Articles submitted to the Gene Therapy Review will now also be directly available in school, college, university, hospital, governmental, corporate and public libraries. EBSCOhost is part of the EBSCO publishing group and functions by providing customers with an integrated service that combines reference databases, subscription management, online journals, books, linking services and A-to-Z solutions. Inclusion in the databases maintained and distributed by EBSCOhost should widen the exposure of the Gene Therapy Review and encourage new and exsiting users to submit new content and help build the most comprehensive source of gene therapy information on the web.